IP Verse

Gedeon Richter Pharma competitive analysis

Latest oppositions filed by Gedeon Richter Pharma

Explore patent oppositions filed by Gedeon Richter Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 10, 2026
Patent NumberTitleApplicantOpposition Date
EP3519049
Safe And Effective Method Of Treating Psoriasis With Anti-Il23 Specific AntibodyJANSSEN BIOTECHSep 1, 2026
EP4019041
Toxicity Management For Anti-Tumor Activity Of CarsTHE CHILDRENS HOSPITAL OF PHILADELPHIASep 28, 2023
EP2578231
Antitumor T Cell Response EnhancerCHUGAI SEIYAKU KABUSHIKI KAISHAJul 25, 2023
EP3433276
Early Intervention Methods To Prevent Or Ameliorate ToxicitySEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RESEARCH INSTITUTESep 20, 2022
EP2872171
Toxicity Management For Anti-Tumor Activity Of CarsTHE CHILDRENS HOSPITAL OF PHILADELPHIAOct 6, 2021
EP3338794
Toxicity Management For Anti-Tumor Activity Of CarsTHE CHILDRENS HOSPITAL OF PHILADELPHIANov 25, 2020
EP2364732
Tumor Therapy With An Antibody For Vascular Endothelial Growth Factor And An Antibody For Human Epithelial Growth Factor Receptor Type 2F HOFFMANN LA ROCHEApr 5, 2017
EP2441472
Tumor Therapy With An Anti-Vegf AntibodyF HOFFMANN LA ROCHEMar 8, 2016

Latest PTAB cases involving Gedeon Richter Pharma

Discover the latest PTAB cases involving Gedeon Richter Pharma, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Gedeon Richter Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GEDEON RICHTER PHARMA8 - - -
F HOFFMANN LA ROCHE34231 - -
THE CHILDRENS HOSPITAL OF PHILADELPHIA - 22 - -
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - 48 - 7